CCR5 and HIV-1 infection: The finding that humans who lack CCR5 expression due to the homozygosity of the Δ32 mutation in the CCR5 gene are resistant to HIV-1 infection [9] stimulated research on CCR5 inhibitors which led to the licensing of Maraviroc (MVC) [10] for clinical use in 2007.